Atherosclerosis
Volume 208, Issue 1 , Pages 56-61 , January 2010

Participation of 5-lipoxygenase-derived LTB4 in 4-hydroxynonenal-enhanced MMP-2 production in vascular smooth muscle cells

  • Kyo W. Seo

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Both authors contributed equally to this work.
    • ,
  • Seung J. Lee

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Both authors contributed equally to this work.
    • ,
  • Chae E. Kim

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • ,
  • Mi R. Yun

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • ,
  • Hye M. Park

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • ,
  • Jung W. Yun

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • ,
  • Sun S. Bae

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • ,
  • Chi D. Kim

      Affiliations

    • MRC for Ischemic Tissue Regeneration and Medical Research Institute, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Department of Pharmacology and BK21 Medical Science Education Center, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-770, Republic of Korea. Tel.: +82 51 510 8063; fax: +82 51 510 8068.

Received 6 April 2009 ,Revised 5 June 2009 ,Accepted 8 June 2009.

References 

  1. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol. 2008;23:381–390
  2. Kumagai T, Ikezoe T, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res. 2004;10:1508–1520
  3. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res. 2005;49:1044–1049
  4. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost. 2005;3:254–267
  5. Lee JY, Jung GY, Heo HJ, et al. 4-Hydroxynonenal induces vascular smooth muscle cell apoptosis through mitochondrial generation of reactive oxygen species. Toxicol Lett. 2006;166:212–221
  6. Sampey BP, Carbone DL, Doorn JA, Drechsel DA, Petersen DR. 4-Hydroxy-2-nonenal adduction of extracellular signal-regulated kinase (Erk) and the inhibition of hepatocyte Erk-Est-like protein-1-activating protein-1 signal transduction. Mol Pharmacol. 2007;71:871–883
  7. Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Rosa A, et al. Role of endogenous interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty, interleukin-10 and primary angioplasty. Int J Cardiol. 2005;99:77–81
  8. Yun MR, Im DS, Lee SJ, et al. 4-Hydroxynonenal contributes to macrophage foam cell formation through increased expression of class A scavenger receptor at the level of translation. Free Radic Biol Med. 2008;45:177–183
  9. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. 2007;5:265–282
  10. Risinger GM, Hunt TS, Updike DL, Bullen EC, Howard EW. Matrix metalloproteinase-2 expression by vascular smooth muscle cells is mediated by both stimulatory and inhibitory signals in response to growth factors. J Biol Chem. 2006;281:25915–25925
  11. Hlawaty H, Jacob MP, Louedec L, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol. 2009;29:518–524
  12. Caird J, Napoli C, Taggart C, Farrell M, Bouchier-Hayes D. Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol. 2006;13:1098–1105
  13. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1–31
  14. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120–126
  15. Jawien J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest. 2006;36:141–146
  16. Back M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res. 2007;100:946–949
  17. Jawien J, Gajda M, Wolkow P, et al. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol. 2008;59:633–639
  18. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA. 2006;103:8161–8166
  19. Zhou YJ, Wang JH, Li L, et al. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem Biophys Res Commun. 2007;363:30–36
  20. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443–449
  21. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003;100:1238–1243
  22. De Caterina R, Zampolli A. From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med. 2004;350:4–7
  23. Jawien J. The putative role of leukotrienes in experimental atherogenesis. Pol Arch Med Wewn. 2009;119:90–93
  24. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664–672
  25. Back M, Bu DX, Branstrom R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA. 2005;102:17501–17506
  26. Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005;112:578–586
  27. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:369–375
  28. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29–37
  29. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233–239
  30. Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670
  31. Radmark O, Samuelsson B. 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat. 2007;83:162–174
  32. Yun MR, Im DS, Lee SJ, et al. 4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase. Free Radic Biol Med. 2009;46:692–698
  33. Lee SJ, Seo KW, Yun MR, et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-kappaB signaling pathways. Free Radic Biol Med. 2008;45:1487–1492
  34. Luo M, Jones SM, Peters-Golden M, Brock TG. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc Natl Acad Sci USA. 2003;100:12165–12170
  35. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23:41–48sponsored by the International Society of Cardiovascular Pharmacotherapy
  36. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262
  37. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10:267–274
  38. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245–253
  39. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695
  40. Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10:966–973
  41. Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA. 2000;97:5261–5266

PII: S0021-9150(09)00489-4

doi: 10.1016/j.atherosclerosis.2009.06.012

Atherosclerosis
Volume 208, Issue 1 , Pages 56-61 , January 2010

Article Tools

* Image Usage & Resolution